PURPOSE 3: Could an Investigational Twice-a-Year Injection Prevent HIV?
Our team of clinical scientists are evaluating an investigational PrEP (pre-exposure prophylaxis) medicine, lenacapavir, to see if it helps to reduce the chance of getting HIV through sex. This clinical trial is supported by, and in partnership, with the HIV Prevention Trials Network (HPTN) and is one of the many trials working to expand global HIV prevention efforts.
Some participants in the study will receive the investigational medicine, which is given as an injection under the skin once every 6 months. Other participants in the study will receive daily emtricitabine/tenofovir disoproxil fumarate (also known as F/TDF or Truvada®) taken by mouth. The active drug you receive may be lenacapavir (1 out of 2 chance) or F/TDF (1 out of 2 chance).
Do you qualify?What Does the Study Involve?
You will first come into the participating site where you will be asked to review and sign an informed consent form. During the initial visit, you will have an HIV test and other lab tests done and be asked more questions by the staff to see if you meet all the eligibility criteria for the study.
If you do not have HIV and meet all the eligibility criteria, you can choose to participate in the second part of the study.
If you are confirmed to have HIV, we will link you to HIV care in your community.
This study will last approximately 2.5 years.
The visits are 4-13 weeks apart, with 4-8 visits per year.
Everyone who enrolls in the study will receive either a daily pill (Truvada, F/TDF) or an injection given every 6 months (lenacapavir).
- Which drug you receive will be determined by chance
- You will receive a study drug, which may be lenacapavir (1 out of 2 chance) or F/TDF (1 out of 2 chance) for approximately 1 year in the first part of the study
- When the first part of the study is over, you will transition to the second phase of the study where everyone receives daily oral F/TDF for approximately 1.5 years
You will first come into the participating site where you will be asked to review and sign an informed consent form. During the initial visit, you will have an HIV test and other lab tests done and be asked more questions by the staff to see if you meet all the eligibility criteria for the study.
If you do not have HIV and meet all the eligibility criteria, you can choose to participate in the second part of the study.
If you are confirmed to have HIV, we will link you to HIV care in your community.
Everyone who enrolls in the study will receive either a daily pill (Truvada, F/TDF) or an injection given every 6 months (lenacapavir).
This study will last approximately 2.5 years.
The visits are 4-13 weeks apart, with 4-8 visits per year.
- Which drug you receive will be determined by chance
- You will receive a study drug, which may be lenacapavir (1 out of 2 chance) or F/TDF (1 out of 2 chance) for approximately 1 year in the first part of the study
- When the first part of the study is over, you will transition to the second phase of the study where everyone receives daily oral F/TDF for approximately 1.5 years
PURPOSE 3 Questionnaire
Thank you for your interest in participating in the PURPOSE 3 study.
Answer these 4 questions to see if you may be eligible to take part in the study:
You may qualify!
If you want to learn more about participating in PURPOSE 3, use our site finder to contact a study site in your area.
You may not qualify, but there are still ways you can help!
You can still help us in our mission by sharing our PURPOSE 3 study with others.
Your privacy matters to us. Note that your answers will only be used to let you know whether or not you qualify, and will not be stored or tracked in any way.
